AstraZeneca PLC Sponsored ADR (AZN.US) Breast Cancer Treatment Trial Fails to Meet Expectations, Stock Price Drops 1.4% in Pre-market Trading

British pharmaceutical giant Astrazeneca PLC Sponsored ADR (AZN.US) announced that an experimental cancer drug, Datopotamab deruxtecan (Dato-DXD), co-developed with Daiichi Sankyo Company, did not extend the survival of patients in a crucial breast cancer treatment trial and did not show significant advantages compared to chemotherapy. In response to this news, the stock price of Astrazeneca PLC Sponsored ADR fell by 1.4% in pre-market trading. The company stated that it will share these trial results with regulatory agencies and discuss whether the drug should be approved for market. The study targeted breast cancer patients who were unable to undergo surgery or had already metastasized, and had hormone receptor-positive, low HER2 expression, or negative breast cancer. Despite showing positive signs in the early stages of the trial, such as prolonging progression-free survival in patients, the final results did not meet expectations. Astrazeneca PLC Sponsored ADR explained that the trial results may have been influenced as patients continued to receive other effective treatments after cancer progression. The company also noted that while the drug only achieved partial positive data in a lung cancer trial earlier this month, they are still committed to developing this drug as a treatment option for breast cancer patients. Datopotamab deruxtecan is an antibody-drug conjugate (ADC) designed to deliver potent chemotherapy drugs directly to cancer cells in order to kill cancer cells while minimizing damage to healthy cells.